Category:
Other Excipients
CAS NO:
/
Standard:
In-house Standards,

"1, Promote the recovery of nerve injury; 2, Treatment for optic nerve injury." "Highlights: 1, National first class new medicine, based on Nobel research results; 2, Highly homologous (over 90%) to that of human NGF; 3, Time to market: 2002 4, Total turnover reached 150 million US dollars in 2013. Registration Dossiers:non-clinical & clinical part, drug substance part and drug product part."